tradingkey.logo

Rapid Micro Biosystems Inc

RPID
2.750USD
-0.120-4.18%
Close 11/06, 16:00ETQuotes delayed by 15 min
121.16MMarket Cap
LossP/E TTM

Rapid Micro Biosystems Inc

2.750
-0.120-4.18%
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison

TradingKey Stock Score of Rapid Micro Biosystems Inc

Currency: USD Updated: 2025-11-06

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Rapid Micro Biosystems Inc's Score

Industry at a Glance

Industry Ranking
112 / 210
Overall Ranking
266 / 4615
Industry
Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 4 analysts
Buy
Current Rating
8.000
Target Price
+178.75%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Rapid Micro Biosystems Inc Highlights

StrengthsRisks
Rapid Micro Biosystems, Inc. is a life sciences technology company providing mission critical automation solutions to facilitate the manufacturing and release of healthcare products, such as biologics, vaccines, cell and gene therapies, and sterile injectables. The Company's flagship Growth Direct system automates and modernizes the antiquated, manual microbial quality control, testing workflows used in pharmaceutical manufacturing operations. It offers four specific applications for testing of microbial contamination: Environmental Monitoring, which tests the manufacturing environment, including circulating air, exposed surfaces, and personnel; Water, which tests any purified water used at any stage of the drug production process, including water for injection; In-Process Bioburden, which tests raw materials, drug substance and in-process product, and Sterility Release offering final testing of finished product to ensure sterility before the product is released for commercial sale.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 63.72% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 28.05M.
Undervalued
The company’s latest PE is -2.75, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 23.66M shares, decreasing 6.24% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 110.99K shares of this stock.

Financial Health

Currency: USD Updated: 2025-11-06

The company's current financial score is 5.97, which is lower than the Healthcare Equipment & Supplies industry's average of 7.46. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 7.26M, representing a year-over-year increase of 9.73%, while its net profit experienced a year-over-year increase of 5.72%.

Score

Industry at a Glance

Previous score
5.97
Change
0

Financials

8.73

Key Metrics

Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
No Data

Quality of Earnings

7.65

Operational Efficiency

2.57

Growth Potential

3.81

Shareholder Returns

7.11

Rapid Micro Biosystems Inc's Company Valuation

Currency: USD Updated: 2025-11-06

The company’s current valuation score is 6.09, which is lower than the Healthcare Equipment & Supplies industry's average of 7.19. Its current P/E ratio is -2.75, which is -81.17% below the recent high of -0.52 and -57.82% above the recent low of -4.33.

Score

Industry at a Glance

Previous score
6.09
Change
0

Valuation Dimensions

P/E
P/B
P/S
P/CF
Industry Ranking 112/210
No Data

Earnings Forecast

Currency: USD Updated: 2025-11-06

The company’s current earnings forecast score is 8.50, which is higher than the Healthcare Equipment & Supplies industry's average of 7.74. The average price target for Rapid Micro Biosystems Inc is 8.00, with a high of 8.00 and a low of 8.00.

Score

Industry at a Glance

Previous score
8.50
Change
0

Support & Resistance

No Data

Analyst Rating

Based on 4 analysts
Buy
Current Rating
8.000
Target Price
+178.75%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

89
Total
4
Median
7
Average
Company name
Ratings
Analysts
Rapid Micro Biosystems Inc
RPID
4
Boston Scientific Corp
BSX
37
Intuitive Surgical Inc
ISRG
35
Edwards Lifesciences Corp
EW
35
Veeva Systems Inc
VEEV
34
Thermo Fisher Scientific Inc
TMO
28
1
2
3
...
18

Financial Forecasting

EPS
Revenue
Net Profit
EBIT
No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-06

The company’s current price momentum score is 6.65, which is lower than the Healthcare Equipment & Supplies industry's average of 6.74. Sideways: Currently, the stock price is trading between the resistance level at 3.34 and the support level at 2.40, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score
6.88
Change
-0.23

Support & Resistance

No Data

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators
Sell(2)
Neutral(4)
Buy(0)
Indicators
Value
Direction
MACD(12,26,9)
-0.043
Sell
RSI(14)
42.041
Neutral
STOCH(KDJ)(9,3,3)
26.525
Neutral
ATR(14)
0.228
High Vlolatility
CCI(14)
-83.501
Neutral
Williams %R
83.051
Oversold
TRIX(12,20)
-0.638
Sell
StochRSI(14)
37.064
Neutral
Moving Average
Sell(6)
Neutral(0)
Buy(0)
Indicators
Value
Direction
MA5
2.812
Sell
MA10
2.863
Sell
MA20
2.968
Sell
MA50
3.050
Sell
MA100
3.175
Sell
MA200
2.946
Sell

Institutional Confidence

Currency: USD Updated: 2025-11-06

The company’s current institutional recognition score is 5.00, which is lower than the Healthcare Equipment & Supplies industry's average of 6.40. The latest institutional shareholding proportion is 59.58%, representing a quarter-over-quarter decrease of 16.42%. The largest institutional shareholder is The Vanguard, holding a total of 904.36K shares, representing 2.28% of shares outstanding, with 19.14% increase in holdings.

Score

Industry at a Glance

Previous score
5.00
Change
0

Institutional Shareholding

No Data

Shareholder Activity

Name
Shares Held
Chg %
Bain Capital Life Sciences Investors, LLC
8.43M
--
Kennedy Lewis Investment Management LLC
4.94M
--
Longitude Capital Management Co., LLC
3.56M
--
Endeavour Medtech Growth II LP
2.26M
--
Ally Bridge Group (HK) Limited
1.85M
--
Schonfeld Strategic Advisors LLC
1.04M
+0.86%
Parkman Healthcare Partners LLC
913.44K
+24.17%
The Vanguard Group, Inc.
Star Investors
904.36K
+1.58%
Advent International L.P.
577.78K
--
Spignesi (Robert G JR)
493.93K
-43.38%
1
2

Risk Assessment

Currency: USD Updated: 2025-11-06

The company’s current risk assessment score is 1.99, which is lower than the Healthcare Equipment & Supplies industry's average of 4.57. The company's beta value is 1.38. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.

Score

Industry at a Glance

Previous score
1.99
Change
0
Beta vs S&P 500 index
1.38
VaR
--
240-Day Maximum Drawdown
+49.23%
240-Day Volatility
+124.98%

Return

Best Daily Return
60 days
+12.95%
120 days
+12.95%
5 years
--
Worst Daily Return
60 days
-10.58%
120 days
-17.79%
5 years
--
Sharpe Ratio
60 days
+0.52
120 days
+0.13
5 years
--

Risk Assessment

Maximum Drawdown
240 days
+49.23%
3 years
+59.80%
5 years
--
Return-to-Drawdown Ratio
240 days
+3.14
3 years
+0.50
5 years
--
Skewness
240 days
+1.05
3 years
+1.15
5 years
--

Volatility

Realised Volatility
240 days
+124.98%
5 years
--
Standardised True Range
240 days
+9.53%
5 years
--
Downside Risk-Adjusted Return
120 days
+18.55%
240 days
+18.55%
Maximum Daily Upside Volatility
60 days
+60.94%
Maximum Daily Downside Volatility
60 days
+53.67%

Liquidity

Average Turnover Rate
60 days
+0.21%
120 days
+0.31%
5 years
--
Turnover Deviation
20 days
-38.37%
60 days
-40.59%
120 days
-12.93%

Peer Comparison

Healthcare Equipment & Supplies
Rapid Micro Biosystems Inc
Rapid Micro Biosystems Inc
RPID
6.14 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Castle Biosciences Inc
Castle Biosciences Inc
CSTL
8.65 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Cencora Inc
Cencora Inc
COR
8.61 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
TCMD
8.60 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
AxoGen Inc
AxoGen Inc
AXGN
8.53 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Artivion Inc
Artivion Inc
AORT
8.51 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
KeyAI